Benzinga | Jul 16, 2021 08:06AM EDT

UBS Initiates Coverage On Anika Therapeutics with Neutral Rating, Announces Price Target of $46

UBS initiates coverage on Anika Therapeutics (NASDAQ:ANIK) with a Neutral rating and announces Price Target of $46.